After news broke over the weekend that Cinven (London), a private equity firm, would be possibly acquiring Medpace (Cincinnati), a contract research organization, the firm confirmed the $915 million acquisition on Monday. The equity structure of the deal will be broadly 80/20 split between Cinven and the management team. Cinven is not disclosing the debt/equity split of the transaction
What if therapies to treat certain cancers and tumors could be more personalized for patients? What if there was a way to derive treatment for a patient based on extracting information from the tumor itself?
It's been a whirlwind of a week for EndoGastric Solutions (San Mateo, California), a company focused on the endoluminal reconstructive treatment for gastroesophageal reflux disease. On one side of the spectrum, the company reported that it has reached a $5.25 million civil settlement with the U.S. Department of Justice related to allegations that it encouraged providers to submit claims for its transoral fundoplication procedures using incorrect procedure codes, and that its co-marketing program was a potential inducement to purchase its products. On the other side of the spectrum the company reported favorable results from data from its Transoral Incisionless Fundoplication (TIF) registry.
Promising results of a multi-center clinical trial evaluating Cognoptix's (Acton, Massachusetts) Sapphire II eye test could bring the firm one step closer to having an approved application to identify Alzheimer's disease. Results of the trial were published in the latest issue of the Journal of Alzheimer's Disease & Other Dementias.
